article thumbnail

STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show

STAT

In study documents, Mount Sinai doctors said the biopsies result in “the same amount of tissue loss” and “in effect, the same level of risk” for patients as standard DBS, because they are removing tissue that would otherwise be cauterized.

article thumbnail

FDA document outlines apparent agency support for full approval of Biogen, Eisai's Leqembi

Fierce Pharma

As Alzheimer's disease partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. | As Alzheimer's partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FDA reviewers had string of concerns about Sarepta’s gene therapy for Duchenne, documents show

STAT

Reviewers at the Food and Drug Administration concluded that Sarepta Therapeutics did not show that its gene therapy for Duchenne muscular dystrophy will likely benefit patients and left key safety concerns, according to briefing documents released Wednesday.

article thumbnail

FDA Drafts Guidance Document for Materials Used in the Manufacture of CGTs and Tissue-Engineered Therapeutics

BioPharm

A new draft guidance issued by FDA covers human- and animal-derived materials used in the manufacture of advanced therapy medicinal products.

article thumbnail

STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show

STAT

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

article thumbnail

STAT+: FDA and Covis release dueling documents over the fate of a controversial drug for premature births

STAT

In the run-up to an extremely unusual hearing later this month, newly released documents underscore highly contrasting views taken by the U.S. For the first time, the FDA has explained in copious detail why agency officials believe the medication, which is called Makena, should be removed.

article thumbnail

FDA cracks down on China's Hengrui in scathing manufacturing write-up

Fierce Pharma

When the FDA comes knocking at your drug manufacturing facility, it’s best to play along. |

FDA 109